The prevalence of saccular unruptured intracranial aneurysms (UIAs) in the general population is 3%.
1 Owing to the rising availability and quality of brain imaging, the number of incidentally discovered UIAs is increasing.
2,3 Many UIAs remain asymptomatic, but some rupture, causing subarachnoid hemorrhage (SAH). This is a subtype of stroke with a poor prognosis (a case-fatality rate of approximately 35%), often affecting relatively young patients (mean age, 60 years).
4 Preventive treatment of UIAs, either by endovascular treatment (EVT) or neurosurgical treatment (NST), can decrease the risk of SAH, but both treatment modalities carry a risk of serious complications.
5 Currently, the decision to treat UIAs is a balance of risk of rupture, risk of treatment complications, life expectancy, and level of patient anxiety. For estimations of the rupture risk, prediction models are available that provide absolute risks of rupture for the next 5 years based on a few easily available risk factors.
6,7 Such robust data are lacking for the estimation of complication risk from UIA treatment.
5,8 The best available evidence comes from meta-analyses published in 2012 and 2013 on the procedural morbidity and case-fatality risk of EVT and NST.
9,10 However, since the publication of these reviews, there has been a further shift toward EVT as the predominant treatment modality, with an increasing variety of advanced endovascular methods being used, such as stent-assisted or balloon-assisted coiling, flow-diverting stents, and Woven EndoBridge (WEB) Aneurysm Embolization devices. In addition, previous meta-analyses did not focus on risk factors for complications apart from subgroup analyses. Our aim is to provide an overview of the recent literature on EVT and NST, with several new focuses. In addition to assessing the procedural 30-day clinical complication and case-fatality risks of both treatment modalities, we conducted a meta-analysis of the available risk factor data for clinical complications from both EVT and NST, and we separately assess the complication risk of advanced endovascular methods that were increasingly applied in clinical practice over the last few years.